Debanjana Chatterjee
Stock Analyst at Jones Trading
(0.75)
# 3,705
Out of 4,784 analysts
7
Total ratings
50%
Success rate
-14.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $11.93 | +151.47% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $7.07 | +225.32% | 1 | Mar 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $42 | $3.71 | +1,032.08% | 1 | Jan 27, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $17.94 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $15.80 | +191.14% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $8.07 | +408.05% | 1 | Sep 17, 2024 |
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $11.93
Upside: +151.47%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $7.07
Upside: +225.32%
Sagimet Biosciences
Jan 27, 2025
Initiates: Buy
Price Target: $42
Current: $3.71
Upside: +1,032.08%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $17.94
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $15.80
Upside: +191.14%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $8.07
Upside: +408.05%